The SENCAR stock of mice has proved to be a useful model in dissecting out the multistage nature as well as the critical mechanisms involved in skin tumorigenesis. This outbred stock was selectively bred to be susceptible to initiation with 7,12-dimethylbenz[a]anthracene (DMBA) and promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA). In order to obtain mice more suitable for genetic analyses of tumor susceptibility and tissue transplantation studies, several inbred lines of mice were derived from the SENCAR stock. One of these lines, the SSIN mice, has a higher susceptibility to tumor promotion compared to the SENCAR stock but is very resistant to tumor progression. On the other hand, the SENCAR B/Pt mice, derived also from the outbred stock, not only have a tumor promotion susceptibility almost identical to the SSIN mice, but they also have a high susceptibility to tumor progression. In order to understand the nature of the phenotypic differences between these two inbred lines we have characterized them using several parameters and markers that are associated with the progression of papillomas to squamous cell carcinoma (SCC). In this sense we analysed the tumor multiplicity and SCC incidence, and the expression of markers of progression and cell cycle related proteins in papillomas derived from both strains. Our results showed that while both strains have a similar papilloma multiplicity and incidence the SENCAR B/Pt mice have 67% incidence of SCC, compared to 0% in the SSIN. SENCAR B/Pt papillomas at 30 weeks of promotion have a higher and aberrant expression of K13, and loss of connexin 26. TGF-β1 was found to be over-expressed in the suprabasal and superficial cells in the SENCAR B/Pt papillomas, while it was only expressed in the superficial cell layer in those derived from SSIN. The SENCAR B/Pt papillomas also showed an enlarged proliferative compartment with overexpression of cyclin D1 and PCNA as seen by immunohistochemistry and Western blot.
Introduction
In the area of chemical carcinogenesis the SENCAR stock of mice has proved to be a useful model in dissecting out the *Abbreviations: BSA, bovine serum albumin; Cx26, connexin 26; DMBA, 7,12-dimethylbenz [a] anthracene; EGF, epidermal growth factor; EGFr, epidermal growth factor receptor; K1, K13, keratins 1 and 13 respectively; PBS, phosphate-buffered saline; SCC, squamous cell carcinoma; TGF-α, TGF-β1, transforming growth factor α and β1 respectively; TPA, 12-Otetradecanoylphorbol-13-acetate.
© Oxford University Press 125 multistage nature as well as the critical mechanisms involved in skin tumorigenesis. This outbred stock was selectively bred to be susceptible to initiation with 7,12-dimethylbenz[a]anthracene (DMBA*) and promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA) (1) , and it has been reported to be one of the more sensitive stocks of mice with regard to tumor initiation and promotion in terms of number of papillomas and the rate of progression of these into squamous cell carcinomas (SCC) (2) .
In order to obtain mice more suitable for genetic analyses of tumor susceptibility and tissue transplantation studies, several inbred lines of mice were derived from the SENCAR stock. Fischer et al. ( 3) using a selective breeding protocol similar to that followed originally by Boutwell followed by brother-sister mating derived the Sensitive SENCAR Inbred strain (SSIN). This inbred strain had a greater sensitivity to TPA promotion, yielding as much as three times the number of papillomas per mouse than the outbred SENCAR stock. They also showed a higher activity of ornithine decarboxylase (ODC) which has been reported as a critical alteration in tumor promotion. These results suggested that the difference in sensitivity between SSIN and the SENCAR stock was probably due to an increased susceptibility to TPA promotion, rather than to DMBA initiation. Later studies by Gimenez-Conti and co-workers (4) , showed that the majority of the papillomas induced by DMBA in the SSIN mice had the same mutation in the Ha-ras-1 gene as those papillomas derived from the outbred SENCAR stock. This suggested that higher susceptibility to the appearance of papillomas could be due to a higher susceptibility to promotion by TPA rather than to an alternative initiation pathway, although the possibility of another initiation site besides the Ha-ras gene cannot be discarded. However, even though the SSIN mice proved to be highly susceptible to tumor promotion they are very resistant to tumor progression. The papillomas in these mice do not progress to SCC or they do it at a very low rate yielding occasionally carcinomas after 50 weeks of promotion.
Independently, Potter and collaborators (5) developed three separate inbred lines from the SENCAR stock, SENCAR lines A, B and C. These lines were developed by brother-sister mating, but without the selective breeding used to develop the SENCAR stock and the SSIN mice. These three lines showed a high promotion susceptibility, but unlike the SSIN mice, papillomas from these strains readily progressed to SCC.
In the last several years we have been interested in the study of papilloma susceptibility to progression to carcinoma in this skin model. We were able to analyse the susceptibility of F1 hybrids between the SENCAR stock and the SSIN, that showed a SCC incidence almost identical to the SENCAR stock (6, 7) . The results of those studies suggested the genetic bases for susceptibility to tumor progression and indicated the presence of at least one dominant gene involved in the susceptible phenotype. The random segregation of the allele/s for the genes that confer susceptibility to tumor progression in the inbreeding of the different lines derived from the outbred SENCAR stock probably determines the differences observed in SCC incidence among the SSIN and SENCAR B/Pt. mice.
The existence of these two lines with almost identical susceptibilities to tumor promotion, but striking differences at the level of tumor progression provides an excellent model to dissect out the events involved in malignant transformation of the epithelial cells in benign papillomas. In order to understand what is the nature of the phenotypic differences between the SSIN and the other inbred lines we decided to characterize these lines using several parameters and markers that can be associated with the ability of papillomas to progress to SCC. To perform this analysis we compared the SSIN to the SENCAR line B (SENCAR B/Pt) derived by Potter and collaborators. As parameters we used the papilloma multiplicity and SCC incidence. We also analysed the expression of markers of progression such as keratin 13 (K13) (8) , integrin α6β4 (9) and connexin 26 (10) (11) (12) in papillomas by immunohistochemistry. In order to determine whether the two strains had differences at the level of tumor proliferation we analysed the expression of cyclin D1, p21, p27, p16, PCNA transforming growth factor (TGF)-α, epidermal growth factor receptor (EGFr) receptor and TGF-β1 on papillomas derived from both strains at the same time of promotion. Given the specificity of the mutation induced by DMBA in the Ha-ras gene during tumor initiation, and the relationship between the Ha-ras gene and the cell cycle clock, we also determined whether there were any differences in the level of expression of this protein in papillomas derived from both strains.
Materials and methods
Tumor experiments SENCAR B/Pt and SSIN mice were obtained from the Veterinary Resources Division of the University of Texas, M.D. Anderson Cancer Center (Bastrop, TX). Six-week-old female SENCAR B/Pt. and SSIN mice were shaved 1-2 days prior to initiation with 10 nmol of DMBA. Promotion was started 2 weeks after initiation and consisted of twice weekly applications of 0.5 µg (SENCAR B/Pt. and SSIN mice) or 0.25 µg (only one group of SENCAR B/Pt. mice) of TPA for 25 weeks. Tumors were counted weekly, at different time points animals were killed, tumors fixed and processed for histology. Tumors derived from mice treated with 0.5 µg of TPA were fixed in formalin, ethanol or were OCT-frozen for immunohistochemical reactions or were snap frozen in liquid nitrogen for protein extraction and Western blot.
Antibodies
Mouse monoclonal anti-TGF-α (Oncogene Science, Uniondale, NY) was used at a concentration of 6 µg/ml. Rabbit polyclonal anti-human cyclin D1 (Upstate Biotechnology, Lake Placid, NY) was used at a 1:100 dilution. Rabbit polyclonal anti-TGF-β1 [anti-LC(1-30-1)] was generously provided by Dr Kathleen Flanders (NCI, NIH, Bethesda, MD), was raised against a synthetic peptide corresponding to the first 30 amino acids of the mature TGF-β1 molecule and was used at a 1:300 dilution. Rat monoclonal anti-mouse α6 integrin subunit (GoH3; Amac, Westbrook, ME) was used at a 1:1000 dilution. Rabbit polyclonal anti-mouse K1 and K13 antibodies were generously provided by Dr Dennis Roop (Baylor College of Medicine, Houston, TX) were used at a 1:500 and 1:800 dilution, respectively. Polyclonal anti-connexin 26 antibody was a generous gift from Dr D.L.Paul (Harvard Medical School, Boston, MA), was raised against the synthetic peptide corresponding to amino acids 108-122 in the cytoplasmic loop and was used at a 1:500 dilution. For Western blot detection primary polyclonal antibodies against cyclin D1, p16, p21, p27, PCNA were purchased from Santa Cruz (Santa Cruz, CA) and monoclonal antibody against Ha-ras was purchased from Oncogene (Cambridge, MA). All these antibodies were used at a dilution of 1 µg/ml. Secondary IgG-horseradish peroxidase conjugated antibodies, anti-rabbit or anti-mouse were purchased from Amersham (Arlington Heights, IL) and were used at a dilution of 1:2000.
Immunohistochemical analysis
Formalin or ethanol-fixed, paraffin-embedded tissues and OCT frozen tissues were cut in serial sections for immunohistochemical analyses. Immunostaining for TGF-α (13), TGF-β1 (14) , cyclin D1 (15), keratin 1 and 13 (6, 8) and connexin 26 (10) was performed as previously described. For immunostaining of integrin subunit α6 frozen sections were air dried for 5 min, fixed with cold acetone for 5 min and incubated with 30% H 2 O 2 in methanol at room temperature for 30 min. The sections were washed with 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS) and incubated with α6 antiserum in 10% rabbit serum at 4°C overnight. The sections were then washed with 1% BSA in PBS and incubated with secondary biotinylated rabbit anti-rat IgG at a 1:220 dilution at room temperature for 30 min. The sections were washed with PBS, incubated with an avidin-biotin-peroxidase system (Vectastain ABC kit, Vector Labs, Burlingame, CA) at room temperature for 30 min and developed with 3,3-diaminobenzidine tetrahydrochloride (DAB). Sections were then lightly counterstained with hematoxylin. All papillomas were confirmed histologically by hematoxylin and eosin staining of sections from every tumor.
Protein extraction and western blot
Frozen tumor samples were ground with liquid nitrogen and resuspended in homogenization buffer (Tris-HCl, 60 mM; EDTA, 5 mM; EGTA, 5 mM; sucrose, 300 mM; DTT, 5 mM; leupeptin, 0.2 mg/ml; PMSF, 2 mM; aprotinin, 20 µg/ml; sodium molybdate, 10 mM; pH 8.6). Samples were then homogenized on ice, sonicated and then centrifuged at maximum speed on a microcentrifuge at 4°C. The supernatant was then centrifuged again for 5Ј at maximum speed. Samples were measured, aliquoted and kept at -80°C until use. Samples (25 or 40 µg) were denatured and analysed by electrophoresis on 7, 10 or 12% polyacrylamide gel electrophoresis (PAGE)-sodium dodecyl sulfate (SDS) gels and transferred to nitrocellulose membranes by electroblotting. Western immunoblotting was carried out as follows: membranes were blocked with a 5% non-fat powder milk in a PBS-Tween (0.125%) solution for 1 h at room temperature, then incubated sequentially with primary antibody (1 µg/ml), anti-rabbit IgG-horseradish peroxidase (1:2000) for 30Ј at room temperature. The peroxidase reaction was detected using the ECL detection system kit (Amersham, Arlington Heights, IL). Figure 1 shows the papilloma multiplicity of two groups of SENCAR B/Pt mice treated with two different TPA doses. Both groups were initiated with 10 nmol of DMBA and promoted with either 0.25 or 0.5 µg of TPA. Mice in these two groups had an incidence of animals with papillomas of 71 and 74%, respectively. The maximum average number of papillomas was 16 at week 17 for the group treated with 0.5 µg of TPA and 12 at week 22 for the group treated with 0.25 µg of TPA. Given the high sensitivity of theses animals to the two stage carcinogenesis protocol many animals had to be killed due to dermatitis. The papilloma multiplicity observed is almost identical to that observed in the SSIN mice under the same protocol (3, 4) .
Results

Tumor experiments
The first SCC appeared at weeks 16 and 19, respectively, for each of the two groups analysed. Both groups reached an incidence of 67% (Table I) . Both experiments were stopped at weeks 35-40 after tumor promotion started because of the high tumor load and mortality.
Analysis of expression of cell cycle-related proteins
Papillomas after 30 weeks of promotion from both inbred strains were analysed for the expression of cyclin D1 by immunohistochemistry. These papillomas were obtained from SENCAR B/Pt. or SSIN mice treated with 10 nmol of DMBA and promoted with 0.5 µg of TPA. The samples analysed for each strain consisted of 27 and 20 papillomas, respectively, for SSIN and SENCAR B/Pt. The criteria used to compare the two strains were the percentage of tumor areas positive for cyclin D1, number of cell layers positive and the pattern of expression in terms of intensity. The results of our analysis showed that while the majority (74%) of the SENCAR B/Pt papillomas had uniform and strong staining, the SSIN papillomas showed a more irregular pattern with only a few (5%) showing an intensity similar to that of the SENCAR B/Pt papilloma (Figure 2A,B) . Regarding the area of the tumor positive for cyclin D1, all SENCAR B/Pt papillomas had 100% of staining, while only 37% of the SSIN papillomas had the entire tumor area positive, the rest of the papillomas showed between 50 and 70% of positive staining (Table II) . In the SSIN papillomas most of the tumors had one to three cell layers stained positive, including the basal cell layer, while only 20% of the tumors analysed had more than three cell layers positive. In the SENCAR B/Pt papillomas 40% of the tumor analysed had more than three cell layers positive for cyclin D1 with many foci that had up to 10 cell layers positive ( Figure 2C,D) .
Regarding the analysis of PCNA expression by immunohistochemistry, the pattern of expression corresponded to that observed for the expression of cyclin D1. In general the positive areas for cyclin D1 were also positive for PCNA, and vice versa for the negative areas. The same correspondence was found in terms of number of cell layers positive ( Figure 2E,F) The expression of cyclin D1, PCNA and cell cycle inhibitors such as p16, p21 and p27 were also analysed by Western blot (Figure 3 ). Proteins were extracted from 30-week-old papillomas, seven samples of SSIN were compared to eight samples from SENCAR B/Pt. The over-expression of cyclin D1 observed by immunohistochemistry was also observed by Western blot. The differences in the level of expression of PCNA were not as striking as the one seen by immunohistochemistry (data not shown). When we looked at the cell cycle inhibitors, we found that there was an over-expression of p16 and p21 in SENCAR B/Pt derived papillomas. In contrast there was no difference in the level of expression of p27.
Analysis of expression of Ha-ras protein
The expression of Ha-ras protein was studied in protein extracts from papillomas after 30 weeks of promotion derived from SSIN or SENCAR B/Pt. mice. As Figure 3 shows, no striking differences were detected in the level of expression of this protein among papillomas derived from both stains and SEN-CAR B/Pt. SCC. Figure 4 shows two representative papillomas after 30 weeks of treatment from the two strains showing their pattern of expression of TGF-β1. In the 24 SSIN papillomas, only seven (30%) had 100% of the tumor positive, the rest of the tumors had between 20 and 70% of their area positive ( Table III) . In 23 of the 24 papillomas analysed (96%) the staining was found in the top superficial layer, with no expression found in the suprabasal or basal cell layers. In the case of the SENCAR B/Pt papillomas, of the 20 
Analysis of expression of TGF-α, EGFr and TGF-β1 by immunohistochemistry
Analysis of expression of tumor progression markers
Papillomas from SSIN and SENCAR B/Pt were analysed for the expression of connexin 26 (Cx26) by immunofluorescence ( Figure 5 ). The intensity and degree of the staining were compared between 10 papillomas from SSIN and 18 from SENCAR B/Pt, all obtained from animals after 30 weeks of treatment. All SSIN papillomas analysed had 100% of the tumor area positive for expression of connexin 26, with the staining localized in the basal cell layer and all the suprabasal cell layers. From the SENCAR B/Pt papillomas analysed, two out of 18 (11%) had 100% staining, although it was restricted to the basal cell layer and only a few of the suprabasal cells. In the rest of the papillomas, seven (38%) had 60-70% of the tumor positive, six (33%) had Ͻ50% and three (17%) were negative. In all cases the staining was only present in the basal cell layer and in few of the suprabasal cells; in many cases the positive cells were restricted to isolated foci, probably corresponding to more differentiated parts of the tumor.
These same papillomas were also analysed for expression of keratin 1 (K1), keratin 13 (K13) and α6β4 integrin. As previously described (4,6) SSIN papillomas at week 30 of promotion showed extensive staining for K1, of the 16 papillomas analysed 75% had between 80 and 100% of the tumor area positive, the rest of the tumors had between 50 and 70% of staining. When we analysed SENCAR B/Pt papillomas, of the 17 analysed only 23% had between 80 and 100% of the tumor area positive, while 58% were either negative or had Ͻ50% positive (Table IV) . Most of the SSIN derived papillomas (93%) had Ͻ50% of the tumor area positive for K13, while 84% of the tumors derived from SENCAR B/Pt had Ͼ50% of the tumor positive for this marker ( Figure 6 ). To analyse the expression of α6β4 integrin we used an antibody that detects the α6 subunit, which can also be conjugated to a β1 polypeptide, but since only α6β4 has been detected in keratinocytes (16), the α6 subunit can be used as a marker for this integrin. When we analysed the expression of α6β4 integrin we found that 100% of the papillomas (15 papillomas) analysed after 30 weeks of promotion derived from SSIN had some aberrant expression of this integrin. In all the tumors besides the normal expression on the basal cell layer the expression of this integrin was aberrantly extended to 3 to 4 cell layers above the basal cells. We also analysed 11 papillomas after 30 weeks of promotion derived from SENCAR B/Pt mice and we found the same pattern of expression. All the papillomas analysed had aberrant foci of expression in the suprabasal cell layers, although given the high level of dysplasia in these tumors it was hard to determine how many suprabasal cell layers were involved ( Figure 6 ).
Discussion
Previous studies have shown not only that tumor promotion and progression are two different and well defined stages, but that they are regulated by different genes (4, 6) . In the present study we found that even though SENCAR B/Pt. mice have a papilloma mutliplicity as high as that observed in the SSIN mice, these mice also have a very high SCC incidence (67%), which is in contrast with that observed in the SSIN mice (almost 0%). The group of mice treated with 0.5 µg of TPA seem to have a higher number of SCC per mouse when compared to the group treated with 0.25 µg of TPA. However, it is hard to make conclusions from SCC multiplicity data since all mice had to be killed soon after the presence of the first SCC is detected because mice bearing SCCs become rapidly emaciated. In this sense, many animals could have developed more SCC given more time rendering the SCC multiplicity data inaccurate.
The striking differences in SCC incidences among SENCAR B/Pt. and SSIN mice provided us with an excellent model to dissect out the critical events in the progression stage. Therefore, we investigated a number of proteins that have been reported to have an altered expression during skin tumor progression in order to determine a sequence of events in the progression of papillomas to SCC.
We studied the expression of cyclin D1 because it is a cell cycle regulatory protein that has been reported to be elevated in a number of neoplasias (17) (18) (19) (20) (21) . Furthermore, previous results from our laboratory have shown that not only there is an over-expression of cyclin D1 during the progression of papillomas, but that this protein is also aberrantly expressed in very early papillomas (15, 22) . The present analysis of expression of cyclin D1 in combination with the analysis of expression of PCNA suggests that those tumors derived from the susceptible strain, SENCAR B/Pt, not only have an enlarged proliferative compartment but the level of expression of cyclin D1 in these cells is increased. The correspondence of expression between cyclin D1 and PCNA as detected by immunohistochemistry suggests that cells over-expressing this cyclin are involved in active proliferation. Nonetheless, there was also expression of cyclin D1 in papillomas derived from the SSIN mice, although it was restricted to the basal cell layer and only a few of the suprabasal cells giving an irregular pattern of expression with an intensity not as strong as the one observed in the SENCAR B/Pt tumors. This same contrast in the expression of cyclin D1 has been detected by Western blot in outbred SENCAR mice derived papillomas at different stages of tumor promotion (Rodriguez-Puebla et al., in preparation). In those studies it was found that there was a dramatic difference between papillomas at 10 and 20 weeks of promo-tion. These data seem to suggest that SSIN papillomas at 30 weeks of promotion resemble 10-week outbred SENCAR papillomas, and also that after 10 weeks of TPA promotion higher levels of cyclin D1 can be observed in papillomas committed to progression.
It has been shown in other models that over-expression of cyclin D1 may be related to activation of the Ha-ras gene (23) (24) (25) . A mutation in codon 61 of the Ha-ras gene is the hallmark of initiation by DMBA in the SENCAR stock, and studies from our laboratory have shown that SSIN papillomas also carry this mutation (4) .
However, the analysis of expression of Ha-ras p21 protein in papillomas derived from both susceptible, SENCAR B/Pt, and resistant, SSIN, mice showed that there were no significant differences in the level of expression of this protein. This finding of similar levels of expression of the Ha-ras protein in papillomas derived from both strains correlates with the finding of Ha-ras mutations in the SSIN mice. A very small increase could be observed in some of the SENCAR B/Pt. papillomas and SCC, but this is probably due to the presence of an extra copy of the Ha-ras gene due to the chromosome 7 trisomy (26). Thus, it is not clear at this time what other genetic differences may account for the different levels of expression of cyclin D1 protein observed between papillomas derived from these two strains. These data seem to suggest that in the SSIN mice the epithelial cells in the papillomas are able to acquire some malignant changes, but they somehow maintain a benign phenotype and do not become fully malignant.
It was interesting to find that not only there was overexpression of cyclin D1, but also of p16, which is an inhibitor of cyclin D-dependent kinases that induces G 1 arrest. Analysis of the expression of p15 and p16 on cell lines derived from skin tumors have shown that there was homozygous loss of p16 and/or p15 genes in a subset of mouse skin carcinomas, but in some spindle cell lines there was an increased expression of these two genes (27) . The authors of those experiments concluded that over-expression of p16 could be due to a loss in Rb function. It seems that functional inactivation of pathways that control phosphorylation of Rb protein are important events in the progression of mouse skin tumors, and this could be achieved by over-expression of cyclin D1, inactivation of p16 or alterations of Rb protein expression with p16 overexpression.
The finding of a slightly higher expression of p21 protein in SENCAR B/Pt. derived papillomas could be a compensation mechanism for the over-expression of cyclin D1. Other experiments performed in our laboratory have shown that there is a significant increase in the number of apoptotic cells in papillomas derived from SENCAR B/Pt. mice when compared to those derived from SSIN mice (28) . An accumulation of p53 protein was also found in those tumors derived from SENCAR B/Pt. mice. The finding of an increase in p21 protein could correlate with the increase in p53 expression and apoptosis.
The role of TGF-β1 in mouse skin carcinogenesis is quite controversial. Experiments done on outbred SENCAR using different promotion protocols in order to generate high or low risk papillomas, suggested that loss of TGF-β1 is a hallmark of tumor progression (29) . On the other hand, experiments done by other groups, also on the SENCAR mouse using the standard two stage protocol, have shown that the over-expression of TGF-β1 seems to be a marker of tumor progression (14, 30) . In the present study we also found over-expression of TGF-β1 in papillomas derived from the progression-susceptible strain, as detected using the anti-LC antibody (31) . It was striking that while SSIN derived papillomas only had expression of TGF-β1 in the superficial cell layer, SENCAR B/Pt. derived papillomas had also expression in suprabasal cells. We also found that in those tumors that had expression of TGF-β1 in the superficial and suprabasal cells 78% had also over-expression of cyclin D1. This correspondence has been also described by Patalamai et al. (14) . In their study they found that most tumors having high levels of Cyclin D1 mRNA also showed high levels of TGF-β1 mRNA. In other carcinogenesis models TGF-β1 has also been shown to either suppress (32) (33) (34) (35) (36) (37) or enhance (38-42) malignant progression. Cui et al. (43) using a transgenic mice model showed that TGF-β1 has biphasic effects acting as a tumor suppressor in early stages of tumor development but later enhancing malignant progression and spindle cell carcinoma conversion. This apparent contradiction can be explained if the initial inhibition of TGF-β1 could lead to the outgrowth of cells with alterations in certain aspects of the TGF-β1 signaling pathway in a way that could lead to an increase in cell proliferation and the ability to undergo a TGF-β1 mediated switch to an invasive phenotype. In this regard, Oft et al. (44) using mammary epithelial cells proposed a model in which TGF-β1 is initially provided by non-tumoral infiltrated cells that in turn activate the expression of TGF-β1 which then induces an epithelialfibroblastoid conversion. These cells acquire invasive properties, become resistant to TGF-β1 induced growth arrest, and begin to produce TGF-β1 themselves in order to maintain the fibroblastoid phenotype. This epithelial-fibroblast-like transdifferentiation has been seen also by Caulin et al. (45) using transformed epidermal cells exposed to TGF-β1. It has been shown that over-expression of cyclin D1 can induce a downregulation of TGF-β type II receptor which leads to resistance to growth inhibition by TGF-β (46) . This could explain our results of correspondence between the over-expression of TGF-β1 and cyclin D1 in papillomas derived from the SENCAR B/Pt.
Experiments have shown that there is an elevated expression of mRNA of both TGF-α and EGFr in late papillomas and SCC in SENCAR mice, suggesting that these alterations in the synthesis of these growth factor/receptor molecules are an important event in the development of autonomous growth in skin papillomas (13) . In the present study we did not find any differences in the level of expression of either TGF-α or EGFr. This finding suggests that SSIN papillomas are able to gain autonomous growth in spite of their terminally benign condition and their rare progression to malignancy. The low rate of regression of SSIN papillomas after TPA treatment has stopped seems to support this hypothesis.
The loss of gap junctional intercellular communication (GJIC) has been shown to be related to carcinogenesis (47) (48) (49) . More specifically in the mouse skin carcinogenesis model it has been found that there is a progressive reduction of GJIC as suggested by the loss of certain gap junction proteins, connexins (Cx), such as Cx26 and Cx43 in malignant skin tumors (10, 12) . Studies performed on the outbred SENCAR revealed that Cx26 is not expressed in adult skin keratinocytes, but it is found in the granular layer of the epidermis after treatment with tumor promoters. However, in late papillomas and SCC there is loss of Cx26, as detected by immunofluorescence, in spite of the high levels of mRNA, which suggests that the loss of expression of this connexin is a post-translational event (10) . Our finding of loss of Cx26 in most of the SENCAR B/Pt. derived papillomas after 30 weeks of promotion is in accordance with the results observed in the outbred SENCAR. The fact that papillomas derived from the SSIN mice have 100% expression of Cx26, in spite of the length of the treatment, suggests that the cells in these tumors are able to undergo a clonal expansion of initiated cells, they acquire the over-expression of Cx26 in order to gain growth advantage but somehow events that confer loss of cell-to-cell communication and later invasion are missing.
Previous studies have shown that while in normal skin the α6β4 integrin is confined to the basal surface of the basal cells, during the progression of papillomas this integrin starts to be expressed in the suprabasal cells (16) . It has been suggested that the aberrant expression of this protein could be a marker of progression and could be related to changes in the motility of cells under conditions of high turnover (9) . In the present study, we found that papillomas derived form both strains had expression of the α6β4 integrin in the basal cell layers and in several suprabasal cells above the basal cells. It has been suggested that the suprabasal expression of α6β4 integrin could be linked to an expansion of the proliferative compartment (9) . Our studies show that SENCAR B/Pt derived papillomas have an enlarged proliferative compartment, as detected by the expression of cyclin D1 and PCNA, compared to those papillomas derived from SSIN. Nonetheless, papillomas derived from SSIN show the aberrant expression of α6β4 in the suprabasal cells. This suggests that the altered expression of this integrin is an early event in the progression of the papillomas, previous to the appearance of K13 and loss of K1, not necessarily linked to an increased proliferation. These results combined with those obtained for the expression of cyclin D1 indicate that probably papillomas in the SSIN mice are able to undergo the malignant conversion pathway, but these cells are later able to maintain control so that the lesions stay benign, and only rarely progress to a more malignant and invasive state. It has been shown that malignant conversion of papillomas to SCC is associated with a switch of mRNA splice variants for the α6 subunit of integrins, from α6A variant in normal epidermis to α6B variant in malignant tumors (50) . This switch in domains of integrin subunits could change the interaction of the integrins with laminin, in a way that could influence the migration and invasive abilities of the tumoral cells (50) . The presence of the α6B variant has not been explored in the present study but it could be speculated that even though SSIN mice derived papillomas have an aberrant expression of α6β4 integrin they may not express the α6B variant that has been associated with a more malignant phenotype.
The fact that SENCAR B/Pt derived papillomas have a higher level of expression of K13, while most of the SSIN papillomas only have scattered cells or Ͻ50% of the tumor area positive confirms the fact that the switch from K1 to K13 is a very good marker of tumor progression and also indicates that the SENCAR B/Pt mice share the same characteristics as the original outbred SENCAR stock in their susceptibility to tumor progression (4, 8) .
The results presented here show that the use of these two strains provides a unique model to dissect out the underlying events of tumor progression. So far the methods available to study tumor progression in the mouse skin model were the use of different protocols of initiation and promotion (51) (52) (53) . The fact that both strains share the same susceptibility to 131 tumor promotion, but dramatically differ in their SCC incidence provides an excellent framework to test several hypotheses on the role of the different genes and proteins known to be involved in the progression of skin tumors. In the present work we were able to determine that, even though tumors derived from SSIN mice are highly differentiated and rarely progress to SCC, they do have alterations in the regulation of proliferation. However, in contrast with the SENCAR B/Pt derived tumors, the SSIN tumor cells are able to avoid progression to malignancy and invasion. We were also able to determine, by comparing these two strains that over-expression of cyclin D1, p16 and p21, loss of expression of Cx26, aberrant expression of TGF-β1 and K1 and K13 switch are relevant markers of tumor progression in this model.
